Sandra Jean Shin, M.D.

Anatomic Pathology and Clinical Pathology
Sandra Shin

Dr. Shin currently serves as Chief of Breast Pathology and Director of the Comprehensive Breast Pathology Consultation Service at the New York Presbyterian Hospital-Weill Cornell Medical College (NYPH-WCMC). She completed her anatomic and clinical pathology training and one-year breast pathology fellowship with Dr. Paul Peter Rosen at the New York Presbyterian Hospital-Cornell campus. After a one year molecular pathology fellowship in the laboratory of Dr. Daniel M. Knowles, she joined the faculty in 2001.  For more than a decade, Dr. Shin has spent her time between clinical service work, translational research, and administrative duties.  Her research in breast disease has led to numerous peer-reviewed scientific publications including chapters in Diagnostic Immunohistochemistry (4 editions), World Health Organization (WHO) Classification of Tumors of the Breast (4th edition), and Breast Pathology (1st edition). She has also served as co-guest editor of Surgical Pathology Clinics; Breast Pathology Issue (2012) and authored a chapter in it entitled "Small Glandular Proliferations of the Breast".  Her scholarly activities in breast pathology have extended into national and international forums, notably her serving as a scientist grant reviewer for the Department of Defense Breast Cancer Research Program for many years and involvement in the United States & Canadian Academy of Pathology (USCAP) annual meeting as an abstract reviewer, moderator for platform sessions, and expert panelist. She participated in the World Health Organization (WHO) consensus editorial meeting in Lyon, France in 2012.  She currently serves on the expert breast pathology committee for the National Cancer Institute (NCI)/ The Cancer Genome Atlas (TCGA). She has given numerous invited lectures on the topic of breast disease across the country as well as internationally (including Mexico, South Korea, Hong Kong, Brazil, Puerto Rico, Bermuda) and is a reviewer or on the editorial board for multiple medical journals. She has directed long courses in breast pathology held at the annual meetings of College of American Pathologists (CAP) and American Society of Clinical Pathologists (ASCP) as well as served as an invited lecturer for the USCAP Diagnostic Pathology Update annual course.  She is also the Pathology Residency Program Director and Breast Pathology Fellowship Director at the NYPH-WCMC.  She is funded and Co-PI of an R01 NIH/NCI grant investigating the pathophysiological role of CUL4A in mammary tumoriogenesis.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Selected Book Chapters:

Shin SJ, et al.  Sections: Tubular Carcinoma and cribriform carcinoma; Benign epithelial proliferations-Adenosis/sclerosing adenosis/apocrine adenosis; Benign epithelial proliferations-Microglandular adenosis; Mesenchymal tumors-Benign vascular lesions: hemangioma, angioma, hemangiopericytoma; Mesenchymal tumors-Pseudoangiomatous stromal hyperplasia.  In Lakhani SR, et al (eds): WHO Classification of Tumors of the Breast; 4th Edition, World Health Organization 2012.

Shin SJ: Nipple Adenoma.  In Dabbs DJ (ed): Breast Pathology, Elsevier Inc., Philadelphia, 2012.

Sahoo S, Shin SJ: Special types of Breast Carcinoma.  In Dabbs DJ (ed): Breast Pathology, Elsevier Inc., Philadelphia, 2012.

Shin SJ, Rabban J: Mesenchymal Tumors of the Breast.  In Dabbs DJ (ed): Breast Pathology, Elsevier Inc., Philadelphia, 2012.

Shin SJ: Breast Tumors in Children.  In Dabbs DJ (ed): Breast Pathology, Elsevier Inc., Philadelphia, 2012.


Most Recent Original Peer-reviewed Scientific Articles:

Kawaguchi K, Shin SJ.  Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast. Am J Surg Pathol 2012;36(7):1009-20.

Ross D, Liu Y-F, Pipa J, Shin SJ. The Diagnostic Utility of the Minimal Carcinoma (MC) Triple Stain in Breast Carcinomas.  Am J Clin Pathol 2013;139(1):62-70.

D’Alfonso TM, Liu Y-F, Chen YB, Cimino-Mathews A, Shin SJ.  SP3, a reliable alternative to HercepTest in determining HER-2/neu (H2N) Status in Breast Cancer Patients.  J Clin Pathol 2013; 66(5):409-14.

Chuang E,  Christos P, Flam A, McCarville K, Forst M,  Shin SJ, Vahdat L, Swistel A, Simmons R, Osborne M, Moore A,  Mazumdar M, Klein  P.  Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health, 2012 Oct;14(5):754-8.

Varma S, Shin SJ.  Spindle cell lesions of the breast. Adv Anat Pathol 2013 Mar; 20(2):95-109.

Shinohara MM, Tozbikian G, Wolfe JT, Shin SJ, Mies C, Elenitsas R.  Cutaneous metastatic breast carcinoma with clear cell features.  J Cutan Pathol 2013;40:753-7.

Zhang Y, Shin SJ, Liu D, Ivanova E, Foerster F, Ying H,  Zheng H, Xiao Y, Chen Z, Protopopov A, DePinho RA. Paik JH.  ZNF365 promotes stability of fragile sites and telomeres.  Cancer Discovery, 2013;3(7):798-811.

D'Alfonso TM, van Laar R, Flinchum R, Brown N, Saint John L, Vahdat L, Shin SJ.   BreastPRS Effectively Separates OncotypeDX Intermediate Risk Group to Low and High Risk Groups.   Breast Cancer Res Treat, 2013;139(3):705-15.

D’Alfonso TM, Wang K, Chiu YL, Shin SJ. Pathologic upgrade rates on subsequent excision (EXBX) when lobular carcinoma in-situ (LCIS) is found in a needle core biopsy (NCB) with radiologic correlation. Arch Pathol Lab Med, 2013;137(7):927-935.

Shin SJ, Lal A, DeVries S, Suzuki J, Roy R, Hwang E, Schnitt SJ, Waldman F, Chen YY.  Florid lobular carcinoma in-situ: molecular profiling and comparison to classic lobular carcinoma in-situ and pleomorphic lobular carcinoma in-situ.  Hum Pathol 2013; 44(10):1998-2009.

Kawaguchi K, Lu F-I, Kaplan R, Liu Y-F, Chadwick P, Chen Z, Brogi E, Shin SJ.  The utilities of immunohistochemical stains GATA-3 and Napsin to distinguish metastatic mammary carcinoma from primary lung adenocarcinoma: a tissue microarray study of 211 cases. Appl Immunohistochem Mol Morph, 2014; 22(4):266-74.

D'Alfonso TM, Ginter PS, Liu YF, Shin SJ.  Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up.   Am J Surg Pathol 2014;38(1):45-53.

Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KSC, Liu H, Bander NH, Shin SJ.  Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS 2014; 122(6):482-9.

Ginter PS, Mosquera JM, MacDonald TY, D'Alfonso TM, Rubin MA. Shin SJ.  FISH MYC Amplification and MYC Protein Expression in Atypical Vascular Lesions, Mammary Angiosarcomas and Angiosarcomas of Other Sites.   Hum Pathol 2014;45(4):709-16.

Wells JM, Pipa J, Shin SJ.  Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 2014:38(3):434-5.

Kaplan R*, Koslow S*, Qiu Q, Chen Z, Swistel A, Shin SJ.  Sentinel Lymph Node Biopsy Is a Reliable Method for Lymph Node Evaluation in Neoadjuvant Chemotherapy Treated Breast Cancer Patients.  Am Surg 2014 Feb; 80(2):171-1. *co-first authors

Nguyen MT, Stessin A, Nagar H, D'Alfonso T, Chen Z, Cigler T, Hayes MK, Shin SJ.  Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Patients.  Clin Breast Cancer 2014;14(3):182-90.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, 6, Glimcher LH. XBP1 promotes triple negative breast cancer and does so by controlling the hypoxia response.  Nature 2014; 508(7494):103-7.

Desman G, Ozerdem U, Shin SJ.  Neighboring look alikes: distinguishing between breast and dermatologic lesions.  Adv Anat Pathol 2014;21(4):228-47.

D’Alfonso TM*, Hannah J*, Liu YF, Chen Z, Zhou P, Shin SJ.  Axl expression in molecular subtypes of breast cancer.  J Clin Pathol 2014 Jun 5 [Epub ahead of print] *co-first authors

Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty A,  Moslehi JJ,  Smalley DM,  Wei X,  Chen X,  Chen Z, Beres JM, Zhang J,     Tsao J, Brenner M, Zhang Y, Fan C, Depinho RA, Perou CM, Paik J, Gygi SP, Kaelin Jr WG, Zhang Q. Prolyl hydroxylation by EgIN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.  Genes Dev 2014; 28:1429-1444.

D’Alfonso TM, Padilla J, MacDonald TY, Mosquera JM, Rubin MA, Shin SJ.  MYB-NFIB gene fusion is present in mammary adenoid cystic carcinoma (ACC) and cylindroma, two morphologically similar entities.  Hum Pathol, in press.

Honors and Awards

  • Distinguished Housestaff Achievement Award. October 21, 2000. Millennium 2000 Alumni Reunion. The New York Hospital-Cornell Medical Center Alumni Council, N.Y., New York.
  • The 1999 Papanicolaou Society of Cytopathology Certificate of Merit for outstanding honorable mention scientific presentation in cytopathology submitted by a pathologist-in-training; March 20, 1999; United States and Canadian Academy of Pathology 88th Annual Meeting, San Francisco.